Is It Safe to Use Compounded Semaglutide and Tirzepatide for Weight Loss?

Demand for Ozempic, Wegovy, and Mounjaro has skyrocketed this year as news gets out about the drugs’ dramatic weight loss results. But many people eager to get their hands on one of these once-a-week injectable medications find themselves struggling for access.

Patients face roadblocks in getting prescriptions and insurance coverage. One issue is that the U.S. Food and Drug Administration (FDA) has only approved Ozempic and Mounjaro for people with type 2 diabetes, not obesity. While doctors can prescribe these medications “off-label” for obesity, insurance companies may deny these claims.

Price is definitely a concern. Without a manufacturer’s coupon or insurance, Wegovy’s cost is $1,350 for a month’s supply, according to its producer, Novo Nordisk.

Pharmaceutical companies are also straining to produce enough of these medications to keep up with demand, leading to shortages.


Leave a Reply

Your email address will not be published. Required fields are marked *